1. Home
  2. BNGO vs LNAI Comparison

BNGO vs LNAI Comparison

Compare BNGO & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.26

Market Cap

12.8M

Sector

Industrials

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

HOLD

Current Price

$2.95

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
LNAI
Founded
2003
N/A
Country
United States
United States
Employees
N/A
29
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
11.7M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BNGO
LNAI
Price
$1.26
$2.95
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
163.2K
3.0M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
94.50
N/A
EPS
N/A
N/A
Revenue
$12,000,735.00
N/A
Revenue This Year
$14.99
N/A
Revenue Next Year
$34.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.26
N/A
52 Week Low
$1.06
$0.15
52 Week High
$5.50
$3.38

Technical Indicators

Market Signals
Indicator
BNGO
LNAI
Relative Strength Index (RSI) 54.72 87.23
Support Level $1.10 $0.89
Resistance Level $1.31 N/A
Average True Range (ATR) 0.06 0.21
MACD 0.00 0.28
Stochastic Oscillator 61.57 87.35

Price Performance

Historical Comparison
BNGO
LNAI

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: